Myelodysplastic syndrome (MDS)
- Risk-stratify by cytopenias, blasts + genetics
- Low-risk disease focuses on anemia/cytopenia support
- ESA/luspatercept or other subtype-directed therapy may help
- Higher-risk disease often uses hypomethylating therapy
- Allogeneic transplant is the only curative option
- Avoid transfusion iron overload over time
Use at a glance
- Risk-stratify by cytopenias, blasts + genetics
Escalation / refractory disease
- ESA/luspatercept or other subtype-directed therapy may help
- Allogeneic transplant is the only curative option
Practical pearls
- Low-risk disease focuses on anemia/cytopenia support
Safety / pitfalls
- Higher-risk disease often uses hypomethylating therapy
- Avoid transfusion iron overload over time
Self-check
- What should be risk-stratified in Myelodysplastic syndrome (MDS)?
by cytopenias, blasts + genetics.
- What should generally be avoided in Myelodysplastic syndrome (MDS)?
transfusion iron overload over time.
Drugs used for this (1)
All clinical uses · Open the interactive console ↗
